phase 2 trial is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-22. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
The online video platform TikTok has had worldwide a social, political, and cultural impact since its global launch in September 2016. The platform has rapidly grown its userbase since its launch and surpassed 2 billion downloads in October 2020. It became the world's most popular website, ahead of Google, for the year 2021.
The sample may be introduced into the column at any time during the column equilibration step or after equilibration has been accomplished. After the volume of eluant surpasses the volume of the mobile phase in the column, the sample components will begin to elute. Compounds with a partition coefficient of unity will elute when one column volume of mobile phase has passed through the column since the time of injection. The compound can then be introduced to another stationary phase to help increase the resolution of results. The flow is stopped after the target compound(s) are eluted or the column is extruded by pumping the stationary phase through the column. An example of a major application of countercurrent chromatography is to take an extremely complex matrix such as a plant extract, perform the countercurrent chromatography separation with a carefully selected solvent system, and extrude the column to recover all of the sample. The original complex matrix will have been fractionated into discrete narrow polarity bands, which may then be assayed for chemical composition or bioactivity. Performing one or more countercurrent chromatography separations in conjunction with other chromatographic and non chromatographic techniques has the potential for rapid advances in compositional recognition of extremely complex matrices.
Flory correctly identified that the chain dimension in polymer melts would have the size computed for a chain in ideal solution if excluded volume interactions were neutralized by experimenting at the theta point. Among his accomplishments are an original method for computing the probable size of a polymer in good solution, the Flory-Huggins Solution Theory, the extension of polymer physics concepts to the field of liquid crystals, and the derivation of the Flory exponent, which helps characterize the movement of polymers in solution.
Candesartan is an angiotensin receptor blocker (ARB) primarily used to treat high blood pressure and congestive heart failure. It is always administered in its inactive prodrug form, candesartan cilexetil, which is converted to the active drug during absorption in the gastrointestinal tract. Like olmesartan, candesartan is a cascading prodrug, a feature that influences its pharmacokinetics. It has good bioavailability and is considered one of the most potent AT1 receptor antagonists by weight. Its effective maintenance dose is also relatively low. It was patented in 1990 and approved for medical use in 1997.
Sources: en.wikipedia.org
=== Diabetes === Processed and unprocessed red meat consumption is a risk factor for developing type 2 diabetes across populations. A 2017 review found that daily consumption of 85 grams of red meat and 35 grams of processed red meat products by European and American consumers increased their risk of type 2 diabetes by 18–36%, while a diet of abstinence of red meat consuming whole grains, vegetables, fruits, and dairy was associated with an 81% reduced risk of diabetes. One study estimated that "substitutions of one serving of nuts, low-fat dairy, and whole grains per day for one serving of red meat per day were associated with a 16–35% lower risk of type 2 diabetes". A 2022 umbrella review found that consuming an additional 100g of red meat per day was associated with a 17% increased risk of type 2 diabetes.
=== Mechanism of action === Plecanatide works as a laxative by drawing water in to the gastrointestinal tract thereby softening stool and encouraging its natural passage. Similar to its endogenous counterpart, plecanatide activates guanylate cyclase-C on endothelial cells within the gastrointestinal tract. The activation of guanylate cyclase-C catalyses the production of the second messenger guanosine 3’,5’-cyclic monophosphate (cGMP) which leads to the protein kinase A (PKA) and protein kinase G II (PKGII)-mediated phosphorylation of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR is an anion channel and upon activation it will secrete negatively charged ions, particularly chloride (Cl−) and bicarbonate (HCO3−) in to the GI tract lumen. This disruption to the electrochemical gradient is in part rectified by the passive secretion of positively charged sodium ions in to the lumen and water follows by osmosis. Plecanatide is also known to have an anti-nociceptive effect in animal models, however the exact mechanism of action is not yet fully elucidated. It has been suggested that this may be in part to the anti-inflammatory action of guanylate cyclase-C by its inhibition of pro-inflammatory cytokines, or through the inhibition of associated sensory neurons.
A systematic review and meta-analysis has shown that cabergoline and quinagolide are more effective in the treatment of hyperprolactinemia compared to bromocriptine, this is because evidence had suggested fewer side effects, rapid titration and offers better dosing interval in medication like quinagolide compared to bromocriptine. Similar studies have been conducted regarding the safety and efficacy of dopamine agonists. According to SUCRA (Surface Under the Cumulative Ranking) and SMAA (Stochastic Multicriteria Acceptability Analysis), quinagolide was found to be the best treatment for women since it can help reduce menstrual irregularities, in addition bromocriptine was shown to be more effective in the treatment for galactorrhea (breast milk production unrelated to pregnancy), and cabergoline was the safest medication as it did not show any alarming side effects. Other dopamine agonists that have been used less commonly to suppress prolactin include dihydroergocryptine, ergoloid, lisuride, metergoline, pergolide, and terguride. If the prolactinoma does not initially respond to dopamine agonist therapy, such that prolactin levels are still high or the tumor is not shrinking as expected, the dose of the dopamine agonist can be increased in a stepwise fashion to the maximum tolerated dose. Another option is to consider switching between dopamine agonists. The prolactinoma can be resistant to bromocriptine but respond well to cabergoline or other dopamine agonists, and vice versa.
=== Committee === WOSM's committee is its executive governing body, composed of elected volunteers and its secretary general, which is responsible for the implementation of the resolutions of its conference and governs the organization between meetings of its conference. The committee meets at least twice a year. Its steering committee, consisting of the chairperson, two vice-chairpersons and its youth advisor and secretary general meet as needed. The committee has 21 members. Twelve, each from a different country, are elected for three-year terms by WOSM's conference. The members, elected without regard to their nationality, represent the interests of the movement as a whole, not those of their country. The secretary general, the treasurer of WOSM and a representative member of the board of the World Scout Foundation and the chairpersons of the regional Scout committees are ex-officio members of the committee. From 2008 to 2021 six Youth Advisors to the WSC were elected by the World Scout Youth Forum. The Youth Advisors participated in all of the WSC meetings and were also part of the governing structure between the meetings. There will be no Youth Advisors from 2024. The 2021–2024 committee set up work streams to address the top strategic priorities, as defined by WOSM's conference. Task forces include:
==== Recent vaccines development in aquaculture ==== There are 24 vaccines available and one for lobsters. The first vaccine was used in the USA against enteric red mouth in 1976. However, there are 19 companies and some small stakeholders are producing vaccines for aquaculture nowadays. The novel approaches are a way forward to prevent the loss of 10% of aquaculture through disease. Genetically modified vaccines are not being used in the EU due to societal concerns and regulations. Meanwhile, DNA vaccines are now authorised in the EU. There are challenges in fish vaccine development, immune response due to lack of potent adjuvants. Scientists are considering microdose application in future. But there are also opportunities in aquaculture vaccinology due to the low cost of technology, regulations change and novel antigen expression and delivery systems. In Norway subunit vaccine (VP2 peptide) against infectious pancreatic necrosis is being used. In Canada, a licensed DNA vaccine against Infectious hematopoietic necrosis has been launched for industry use. Fish have large mucosal surfaces, so the preferred route is immersion, intraperitoneal and oral respectively. Nanoparticles are in progress for delivery purposes. The common antibodies produced are IgM and IgT. Normally booster is not required in fish because more memory cells are produced in response to the booster rather than an increased level of antibodies. mRNA vaccines are alternative to DNA vaccines because they are more safe, stable, easily producible at a large scale and mass immunization potential.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.